Mycio Wealth Partners LLC lessened its stake in shares of Eli Lilly And Co (NYSE:LLY) by 9.4% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,083 shares of the company’s stock after selling 737 shares during the period. Mycio Wealth Partners LLC’s holdings in Eli Lilly And Co were worth $785,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of LLY. Thoroughbred Financial Services LLC raised its holdings in shares of Eli Lilly And Co by 11,124.4% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 854,403 shares of the company’s stock worth $85,440,000 after acquiring an additional 846,791 shares during the period. Bessemer Group Inc. increased its position in shares of Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock worth $63,096,000 after purchasing an additional 546,307 shares during the last quarter. Goelzer Investment Management Inc. increased its position in shares of Eli Lilly And Co by 1,345.5% during the 1st quarter. Goelzer Investment Management Inc. now owns 312,151 shares of the company’s stock worth $40,505,000 after purchasing an additional 290,557 shares during the last quarter. Stevens Capital Management LP increased its position in shares of Eli Lilly And Co by 3,550.1% during the 2nd quarter. Stevens Capital Management LP now owns 273,389 shares of the company’s stock worth $30,289,000 after purchasing an additional 265,899 shares during the last quarter. Finally, Schafer Cullen Capital Management Inc increased its position in shares of Eli Lilly And Co by 30.3% during the 2nd quarter. Schafer Cullen Capital Management Inc now owns 1,030,446 shares of the company’s stock worth $111,587,000 after purchasing an additional 239,590 shares during the last quarter. Institutional investors and hedge funds own 78.92% of the company’s stock.

In other news, VP Michael J. Harrington sold 16,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the transaction, the vice president now directly owns 110,300 shares of the company’s stock, valued at $12,874,216. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joshua L. Smiley acquired 426 shares of the stock in a transaction dated Wednesday, June 5th. The shares were bought at an average cost of $118.03 per share, with a total value of $50,280.78. Following the completion of the transaction, the chief financial officer now owns 30,410 shares of the company’s stock, valued at approximately $3,589,292.30. The disclosure for this purchase can be found here. Insiders own 0.11% of the company’s stock.

A number of analysts recently issued reports on LLY shares. TheStreet downgraded Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. BMO Capital Markets raised their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Edward Jones raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $123.49.

NYSE LLY traded up $0.87 during trading on Wednesday, hitting $111.88. The stock had a trading volume of 85,254 shares, compared to its average volume of 4,170,914. The company has a market capitalization of $108.29 billion, a PE ratio of 20.13, a PEG ratio of 1.95 and a beta of 0.19. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The firm has a 50 day moving average price of $110.61 and a 200 day moving average price of $117.89. Eli Lilly And Co has a twelve month low of $103.65 and a twelve month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. Eli Lilly And Co’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.48 EPS. On average, sell-side analysts anticipate that Eli Lilly And Co will post 5.72 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.31%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How to Invest in Marijuana Stocks

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.